The carbomer-lecithin adjuvant Adjuplex has potent immunoactivating properties and elicits protective adaptive immunity against influenza virus challenge in mice

Wegmann, Frank, Moghaddam, Amin E., Schiffner, Torben, Gartlan, Kate H., Powell, Timothy J., Russell, Rebecca A., Baart, Matthijs, Carrow, Emily W. and Sattentau, Quentin J. (2015) The carbomer-lecithin adjuvant Adjuplex has potent immunoactivating properties and elicits protective adaptive immunity against influenza virus challenge in mice. Clinical and Vaccine Immunology, 22 9: 1004-1012. doi:10.1128/CVI.00736-14


Author Wegmann, Frank
Moghaddam, Amin E.
Schiffner, Torben
Gartlan, Kate H.
Powell, Timothy J.
Russell, Rebecca A.
Baart, Matthijs
Carrow, Emily W.
Sattentau, Quentin J.
Title The carbomer-lecithin adjuvant Adjuplex has potent immunoactivating properties and elicits protective adaptive immunity against influenza virus challenge in mice
Journal name Clinical and Vaccine Immunology   Check publisher's open access policy
ISSN 1556-679X
Publication date 2015-09-01
Year available 2015
Sub-type Article (original research)
DOI 10.1128/CVI.00736-14
Open Access Status DOI
Volume 22
Issue 9
Start page 1004
End page 1012
Total pages 9
Place of publication Washington, DC United States
Publisher American Society for Microbiology
Collection year 2016
Language eng
Formatted abstract
The continued discovery and development of adjuvants for vaccine formulation are important to safely increase potency and/or reduce the antigen doses of existing vaccines and tailor the adaptive immune response to newly developed vaccines. Adjuplex is a novel adjuvant platform based on a purified lecithin and carbomer homopolymer. Here, we analyzed the adjuvant activity of Adjuplex in mice for the soluble hemagglutinin (HA) glycoprotein of influenza A virus. The titration of Adjuplex revealed an optimal dose of 1% for immunogenicity, eliciting high titers of HA-specific IgG but inducing no significant weight loss. At this dose, Adjuplex completely protected mice from an otherwise lethal influenza virus challenge and was at least as effective as the adjuvants monophosphoryl lipid A (MPL) and alum in preventing disease. Adjuplex elicited balanced Th1-/Th2-type immune responses with accompanying cytokines and triggered antigen-specific CD8+ T-cell proliferation. The use of the peritoneal inflammation model revealed that Adjuplex recruited dendritic cells (DCs), monocytes, and neutrophils in the context of innate cytokine and chemokine secretion. Adjuplex neither triggered classical maturation of DCs nor activated a pathogen recognition receptor (PRR)-expressing NF-κB reporter cell line, suggesting a mechanism of action different from that reported for classical pathogen-associated molecular pattern (PAMP)-activated innate immunity. Taken together, these data reveal Adjuplex to be a potent and well-tolerated adjuvant with application for subunit vaccines.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 06 Nov 2015, 19:16:08 EST by System User on behalf of School of Medicine